X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1048) 1048
Publication (115) 115
Book Review (31) 31
Book / eBook (14) 14
Book Chapter (12) 12
Conference Proceeding (1) 1
Data Set (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (743) 743
index medicus (568) 568
oncology (491) 491
melanoma (476) 476
high-risk (441) 441
high-risk melanoma (386) 386
female (321) 321
male (311) 311
cancer (277) 277
middle aged (247) 247
adult (232) 232
cutaneous melanoma (213) 213
melanoma - pathology (213) 213
aged (203) 203
malignant-melanoma (196) 196
skin neoplasms - pathology (196) 196
dermatology (183) 183
immunotherapy (170) 170
melanoma - therapy (150) 150
metastatic melanoma (139) 139
adjuvant therapy (136) 136
surgery (135) 135
prognosis (134) 134
melanoma - diagnosis (130) 130
neoplasm staging (130) 130
research (130) 130
care and treatment (129) 129
melanoma - drug therapy (129) 129
cooperative-oncology-group (120) 120
skin neoplasms - diagnosis (120) 120
diagnosis (118) 118
skin cancer (117) 117
risk factors (112) 112
skin neoplasms - therapy (102) 102
metastasis (101) 101
survival (100) 100
antineoplastic agents - therapeutic use (97) 97
adolescent (96) 96
therapy (94) 94
aged, 80 and over (93) 93
health aspects (92) 92
skin neoplasms - drug therapy (92) 92
melanoma - surgery (89) 89
chemotherapy (84) 84
chemotherapy, adjuvant (84) 84
interferon (83) 83
tumors (83) 83
treatment outcome (81) 81
young adult (80) 80
follow-up (77) 77
article (74) 74
interferon-alpha - therapeutic use (74) 74
medicine, research & experimental (72) 72
melanoma - mortality (72) 72
skin neoplasms - surgery (72) 72
american joint committee (70) 70
animals (69) 69
cutaneous malignant-melanoma (66) 66
melanoma - immunology (64) 64
child (61) 61
medicine & public health (61) 61
skin neoplasms - mortality (61) 61
immunology (60) 60
mutation (60) 60
genetic aspects (59) 59
ipilimumab (59) 59
management (59) 59
high-dose interferon-alpha-2b (58) 58
high-risk neuroblastoma (58) 58
lymphatic metastasis (58) 58
review (58) 58
analysis (57) 57
biopsy (57) 57
disease-free survival (56) 56
melanoma - secondary (56) 56
retrospective studies (55) 55
sentinel lymph node biopsy (55) 55
abridged index medicus (54) 54
colony-stimulating factor (54) 54
usage (54) 54
trial (53) 53
dose interferon-alpha-2b (52) 52
follow-up studies (52) 52
stage-iii melanoma (52) 52
survival rate (52) 52
clinical trials (51) 51
skin (51) 51
interferon-alpha (50) 50
melanoma - genetics (50) 50
metastases (50) 50
prevention (49) 49
surveillance (49) 49
medical research (48) 48
patients (48) 48
hematology, oncology and palliative medicine (47) 47
positron-emission-tomography (47) 47
cancer therapies (46) 46
medical prognosis (46) 46
medicine, general & internal (46) 46
neuroblastoma (46) 46
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1029) 1029
German (20) 20
French (11) 11
Korean (5) 5
Spanish (4) 4
Czech (1) 1
Greek (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The Lancet, ISSN 0140-6736, 09/2018, Volume 392, Issue 10151, pp. 971 - 984
Cutaneous melanoma causes 55 500 deaths annually. The incidence and mortality rates of the disease differ widely across the globe depending on access to early... 
LYMPH-NODE DISSECTION | HIGH-RISK MELANOMA | MEDICINE, GENERAL & INTERNAL | TERT PROMOTER MUTATIONS | DABRAFENIB PLUS TRAMETINIB | STAGE-III MELANOMA | PRIMARY CUTANEOUS MELANOMA | OPEN-LABEL | INVESTIGATOR-CHOICE CHEMOTHERAPY | INDIVIDUAL PATIENT DATA | AMERICAN JOINT COMMITTEE | Melanoma - epidemiology | Melanoma - etiology | Age Distribution | Neoplasm Metastasis - therapy | Skin Neoplasms - therapy | Humans | Risk Factors | Antineoplastic Agents - therapeutic use | Skin Neoplasms - epidemiology | Ultraviolet Rays - adverse effects | Incidence | Randomized Controlled Trials as Topic | Sunlight - adverse effects | Mass Screening | Protein Kinase Inhibitors - therapeutic use | Skin Neoplasms - mortality | Skin Neoplasms - etiology | Melanoma - therapy | Neoplasm Staging | Melanoma - mortality | Medical colleges | Mortality | Melanoma | Antibodies | Metastasis | Epidemiology | Viral antibodies | Analysis | Skin | Mitogens | Protein kinases | Germany | Medical informatics | Medical innovations | Clinical trials | Raf protein | Family medical history | Kinases | Cancer therapies | Metastases | Skin cancer | Proteins | Signal transduction | Age | Containment | Medical research | Threonine | MAP kinase | Protein kinase inhibitors | Survival | Chemotherapy | Sunburn & sun tanning | Inhibitors | Cell death | Mutation | Health risk assessment | Prolongation | Cancer | Tumors
Journal Article
Journal of Surgical Oncology, ISSN 0022-4790, 10/2019, Volume 120, Issue 5, pp. 873 - 881
Current recommendations by the United States Preventive Services Task Force do not support screening for skin cancer. Melanoma is unique among cancers because... 
skin cancer | melanoma | screening | UNITED-STATES | SURGERY | AMERICAN-ACADEMY | FOLLOW-UP | DIAGNOSTIC-ACCURACY | NONMELANOMA SKIN-CANCER | ONCOLOGY | HIGH-RISK | CUTANEOUS MELANOMA | ULTRAVIOLET-RADIATION | SELF-EXAMINATION | Diagnosis | Medicine, Preventive | Melanoma | Cancer | Preventive health services | Skin cancer
Journal Article
JNCCN Journal of the National Comprehensive Cancer Network, ISSN 1540-1405, 03/2012, Volume 10, Issue 3, pp. 366 - 400
Journal Article
MEDECINE NUCLEAIRE-IMAGERIE FONCTIONNELLE ET METABOLIQUE, ISSN 0928-1258, 01/2019, Volume 43, Issue 1, pp. 125 - 137
Journal Article
The Lancet, ISSN 0140-6736, 2005, Volume 365, Issue 9460, pp. 687 - 701
Journal Article